Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DB-007-4
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Natural Sciences and Engineering Council
Deal Size : $0.4 million
Deal Type : Funding
Derm-Biome and TransBIOtech Awarded $450,000 Research Grant Funding
Details : The net proceeds will support Derm-Biome’s preclinical research activities for DB-007-4, a potential best-in-class, first line topical treatment focusing on inflammatory diseases and healthy aging.
Brand Name : DB-007-4
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 08, 2024
Lead Product(s) : DB-007-4
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Natural Sciences and Engineering Council
Deal Size : $0.4 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Derm-Biome Topical Therapy Shows Positive Results in Preclinical Skin Cancer Trial
Details : The company has developed a topical anticancer treatment for patients with or at high risk of developing multiple AKs. It is being evaluated for the treatment of squamous cell carcinoma tumors.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
April 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DB-007-4
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Derm-Biome Pharmaceuticals Begins Ind-Enabling Studies for Db-007-4 for Skin Diseases
Details : DB-007-4 is a potential best-in-class, first line topical treatment which is being evaluated for inflammatory skin diseases such as acne, atopic dermatitis (AD), and rosacea.
Brand Name : DB-007-4
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
February 27, 2024
Lead Product(s) : DB-007-4
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Massachusetts General Hospital
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to study the second-generation topical treatment for precancerous skin conditions (such as actinic keratosis) and non-melanoma skin cancers that is highly selective for cancer cells while being well-tolerated by normal skin.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
November 28, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Massachusetts General Hospital
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Derm-Biome Pharmaceuticals have topical lead compounds for inflammatory skin diseases (acne and atopic dermatitis) and skin cancer that are both highly effective and well tolerated by skin. The company is currently advancing their lead products to phase ...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Derm-Biome’s newly developed compounds far outperformed crisaborole blocking the development of skin inflammation in a mouse model of atopic dermatitis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2022
Lead Product(s) : Crisaborole
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Two of its topical drugs produced significant inhibitory effects in a well-established mouse model of atopic dermatitis (AD). These novel compounds were submitted in US patent application for itchy inflammatory skin disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Derm-Biome will look to show efficacy with its topical drug over a range of chronic inflammatory skin diseases, such as acne and rosacea, as well as skin rejuvenation (anti-ageing).
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
June 29, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
Details : Derm-Biome's topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of psoriasis. The drug showed comparable inhibitory effects to tapinarof over a similar range of concentrations.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2020
Lead Product(s) : Tapinarof
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?